Valuation: Atossa Therapeutics, Inc.

Market Cap 2.03Cr 1.76Cr 1.64Cr 1.5Cr 2.83Cr 193.83Cr 2.88Cr 19Cr 7.57Cr 97Cr 7.63Cr 7.46Cr 322.95Cr P/E 2026 *
-0.54x
P/E 2027 * -0.68x
Enterprise Value 2.03Cr 1.76Cr 1.64Cr 1.5Cr 2.83Cr 193.83Cr 2.88Cr 19Cr 7.57Cr 97Cr 7.63Cr 7.46Cr 322.95Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.2%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day+2.12%
1 week+11.06%
Current month+16.43%
1 month+1.69%
3 months-56.18%
6 months-50.00%
Current year-72.77%
1 week 2.18
Extreme 2.18
2.45
1 month 2.05
Extreme 2.05
2.6
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
64.65
10 years 1.7
Extreme 1.7
756
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap.
20/01/26 Free

Chief Executive Officer

12,81,674 0.9922%
20/01/26
Ensisheim Partners LLC
OtherCompany 0 0%
14/10/25 Free

Chief Financial Officer

5,78,000 0.4595%
Change 5-day change 1-year change 3-year change Capi.($)
+3.81%+11.06%-78.95%-84.40% 2.03Cr
+1.29%+3.46%+7.10%+16.36% 4.95TCr
+0.47%+12.90%+493.60%+590.98% 4.4TCr
+3.34%+14.00%+23.45%+80.73% 3.96TCr
+1.56%+3.32%+33.88%+8.71% 3.93TCr
+0.85%+7.66%+21.22%+48.78% 3.24TCr
-1.31%+4.30% - - 1.68TCr
+0.89%+3.96%+32.51%+122.68% 1.65TCr
+0.34%+3.40%+5.70%+18.79% 1.4TCr
+1.53%+16.87%+81.17%+23.99% 1.28TCr
Average +0.97%+6.97%+68.85%+91.85% 2.65TCr
Weighted average by Cap. +1.03%+5.95%+107.46%+139.11%

Financials

2026 *2027 *
Net sales - -
Net income -3.74Cr -3.24Cr -3.03Cr -2.77Cr -5.21Cr -356.63Cr -5.29Cr -35Cr -14Cr -178.41Cr -14Cr -14Cr -594.22Cr -3.93Cr -3.4Cr -3.18Cr -2.91Cr -5.48Cr -374.94Cr -5.56Cr -37Cr -15Cr -187.57Cr -15Cr -14Cr -624.73Cr
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
10/26/10 $2.430 +2.95% 36,139
07/26/07 $2.360 -2.48% 78,020
06/26/06 $2.420 +1.26% 30,786
05/26/05 $2.390 +3.46% 36,767
04/26/04 $2.310 +6.45% 54,974
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.360USD
Average target price
22.00USD
Spread / Average Target
+832.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock